Insulin, glucagon and somatostatin in the perfused rat pancreas and the effects of HB 699 (4- (2- (5-chloro-2-metoxy-benzamido) -ethyl) -benzoic acid)
Efendić, S.; Enzmann, F.; Gutniak, M.; Nylén, A.; Zoltobrocki, M.
Acta Endocrinologica 98(4): 573-579
1981
ISSN/ISBN: 0001-5598 PMID: 6118003 Document Number: 172699
HB 699 (100 .mu.g/ml), almost identical with the left residue of the sulfonylurea glibenclamide, enhanced basal insulin and somatostatin release from the perfused rat pancreas. The compound also augmented both the early and the late insulin release stimulated by 6.7 mM glucose, while with 16.7 and 33.3 mM glucose only late insulin release was increased. Furthermore, HB 699 enhanced both phases of glucose induced somatostatin release irrespective of whether 6.7, 16.7 or 33.3 mM glucose were used. As for glucagon release, HB 699 suppressed basal and arginine stimulated glucagon secretion. The sulfonylurea moiety of glibenclamide apparently is not a prerequisite for its stimulatory action on insulin and somatostatin release. The enhanced somatostatin release apparently mediates the inhibitory effect of the compound on glucagon release.